Study guide
6.2 Gastrointestinal Pharmacology
DHA Pharmacist Licensing Assessment PHO5481
Track your progress as you read
Finished sections get a check mark.
1 Exam Overview & Licensing Pathway
1.1 Current Exam Facts & Format 1.2 Eligibility, PQR & the Sheryan Application Process 1.3 Study Strategy & Test-Day Plan
2 Cardiovascular Pharmacology
2.1 Antihypertensives & RAAS Agents 2.2 Heart Failure & Antiarrhythmic Drugs 2.3 Lipid-Lowering & Antianginal Agents
3 Endocrine & Metabolic Pharmacology
3.1 Insulin & Oral Antidiabetic Agents 3.2 Thyroid, Bone & Calcium Agents 3.3 Corticosteroids & Other Hormonal Agents
4 Anti-Infective Pharmacology
4.1 Beta-Lactam Antibiotics 4.2 Non-Beta-Lactam Antibacterials 4.3 Antifungals, Antivirals & Antituberculars
5 CNS, Psychiatric & Pain Pharmacology
5.1 Psychiatric Pharmacology 5.2 Antiepileptics & Neurologic Agents 5.3 Analgesics: NSAIDs, Opioids & Migraine
6 Respiratory, GI & Hematology Pharmacology
6.1 Respiratory Pharmacology 6.2 Gastrointestinal Pharmacology 6.3 Anticoagulants, Antiplatelets & Hematology Agents
7 Pharmaceutical Care: Cardiometabolic Disease
7.1 Diabetes Management & Counseling 7.2 Hypertension & Dyslipidemia Management 7.3 Heart Failure & Anticoagulation Management
8 Pharmaceutical Care: Respiratory, Rheumatology & Infection
8.1 Asthma & COPD Management 8.2 Gout, Pain & Rheumatologic Care 8.3 Infection Management & Antimicrobial Stewardship
9 Counseling, Monitoring & Special Populations
9.1 Patient Counseling, Adherence & Health Literacy 9.2 Therapeutic Monitoring & Laboratory Interpretation 9.3 Pregnancy, Pediatrics, Geriatrics & Organ Impairment 9.4 Pharmacoeconomics & Formulary Decision Making
10 Pharmaceutical Calculations I
10.1 Concentration, Ratio & Percentage Strength 10.2 Weight-Based & BSA Dosing 10.3 Dilution, Concentration & Alligation
11 Pharmaceutical Calculations II
11.1 Infusion Rates & IV Flow Calculations 11.2 Dispensing Quantities & Days' Supply 11.3 Compounding Calculations, Isotonicity & Milliequivalents
12 UAE Pharmacy Law & Regulation
12.1 UAE Regulatory Framework & Licensing Authorities 12.2 Medicine Registration, Pricing & Supply Chain 12.3 Prescription Requirements & Validity
13 Controlled Drugs, Ethics & Pharmacovigilance
13.1 Controlled & Semi-Controlled Medicines in the UAE 13.2 Ethics, Confidentiality & Generic Substitution 13.3 Pharmacovigilance, Recall & Medicine Disposal
14 Pharmacokinetics I: ADME
14.1 Absorption & Bioavailability 14.2 Distribution & Protein Binding 14.3 Metabolism & Elimination
15 Pharmacokinetics II: Kinetics, Dosing & TDM
15.1 Half-Life, Clearance & Kinetic Order 15.2 Loading & Maintenance Dosing 15.3 Therapeutic Drug Monitoring
16 OTC Medicines & Self-Care
16.1 Cough, Cold & Allergic Rhinitis 16.2 GI Self-Care: Heartburn, Constipation & Diarrhoea 16.3 Pain & Fever Self-Care 16.4 Referral Red Flags, Emergency Contraception & Skin
17 Medication Safety
17.1 High-Alert Medications & Error-Prone Abbreviations 17.2 Medication Reconciliation & Duplicate Therapy 17.3 Adverse Drug Reactions & Hypersensitivity Recognition
18 Sterile & Nonsterile Compounding
18.1 Aseptic Technique & Compounding Environments 18.2 Parenteral, TPN & Cytotoxic Preparation 18.3 Nonsterile Compounding
19 Pharmaceutics, Biopharmaceutics & Toxicology
19.1 Dosage Form Design & the Biopharmaceutics Classification System 19.2 Dissolution & Excipients 19.3 Toxicology: Poisoning Recognition & Antidotes
20 Infection Control, Natural Products, Medicinal Chemistry & Pharmacogenomics
20.1 Infection Control & Immunization 20.2 Pharmacognosy & Dietary Supplements 20.3 Medicinal Chemistry Essentials 20.4 Clinical Pharmacogenomics
6.2 Gastrointestinal Pharmacology
Key Takeaways Explain This Topic AI
Proton pump inhibitors irreversibly block the H+/K+-ATPase proton pump; long-term use is linked to hypomagnesemia, vitamin B12 deficiency, Clostridioides difficile infection and fractures
Omeprazole inhibits CYP2C19 and reduces activation of the clopidogrel prodrug - pantoprazole is the preferred PPI when a patient takes clopidogrel
Antacids and sucralfate chelate tetracyclines, fluoroquinolones, iron and levothyroxine; separate administration by at least 2-4 hours
Metoclopramide causes extrapyramidal side effects and treatment should not exceed 5 days; ondansetron and domperidone prolong the QT interval
Loperamide must be avoided in bloody diarrhea or suspected invasive bacterial colitis because slowing gut motility can precipitate toxic megacolon
Last updated: August 2026
- Acid-Suppressing Therapy
- Proton Pump Inhibitors
Proton pump inhibitors (PPIs) - omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole - irreversibly inhibit the H+/K+-ATPase (proton pump) on the parietal cell, the final common pathway of gastric acid secretion. Because they bind actively secreting pumps, they work best taken 30-60 minutes before the first meal of the day . Acid suppression takes 1-3 days to reach full effect since new pumps must be synthesised.
Long-term PPI use carries risks the exam expects you to counsel on: hypomagnesemia (impaired intestinal absorption, occasionally with hypocalcemia and tetany), reduced vitamin B12 and iron absorption, increased Clostridioides difficile and enteric infections, community-acquired pneumonia, and hip and vertebral fractures with chronic high-dose use. Use the lowest effective dose and review the indication regularly.
The most tested interaction: omeprazole (and esomeprazole) inhibit CYP2C19 , the enzyme that converts the prodrug clopidogrel into its active antiplatelet metabolite, reducing its effect and raising cardiovascular event risk. When a PPI is needed with clopidogrel, choose pantoprazole (or lansoprazole), which inhibits CYP2C19 far less.
H2 Receptor Antagonists, Antacids and Sucralfate
H2 receptor antagonists (famotidine; ranitidine was withdrawn worldwide because of N-nitrosodimethylamine contamination) competitively block histamine H2 receptors on parietal cells. They are weaker than PPIs, useful for mild reflux and nocturnal acid breakthrough, but tolerance (tachyphylaxis) develops with continuous use. Antacids (aluminium, magnesium, calcium salts) neutralise existing acid for rapid short-lived relief; magnesium salts cause diarrhea, aluminium and calcium cause constipation. The key safety point is chelation : divalent and trivalent cations bind tetracyclines, fluoroquinolones, oral iron, bisphosphonates and levothyroxine , markedly reducing their absorption - separate doses by at least 2-4 hours . Sucralfate forms a protective barrier over ulcer bases in the presence of acid, so give it on an empty stomach and away from other drugs, which it can adsorb.
Helicobacter pylori Eradication
Standard triple therapy combines a PPI with clarithromycin plus amoxicillin (substitute metronidazole in penicillin allergy) for 14 days . Where clarithromycin resistance is high, bismuth quadruple therapy (PPI + bismuth + tetracycline + metronidazole) is preferred. Confirm eradication with a urea breath test or stool antigen test at least 4 weeks after antibiotics finish , and stop the PPI 2 weeks before testing to avoid false negatives.
Antiemetics
- Agent Class / Mechanism Key adverse effect or limit
- Ondansetron 5-HT3 receptor antagonist QT prolongation , constipation, headache
Metoclopramide Dopamine D2 antagonist + prokinetic Extrapyramidal symptoms (acute dystonia, parkinsonism); limit to 5 days ; caution in young adults
Domperidone Peripheral D2 antagonist (minimal CNS penetration) QT prolongation / ventricular arrhythmia; avoid with QT-prolonging drugs
Hyoscine (scopolamine) Antimuscarinic Motion sickness; dry mouth, drowsiness, urinary retention
Aprepitant Neurokinin-1 (NK1) antagonist Chemotherapy-induced nausea; CYP3A4 interactions (reduces warfarin INR)
Laxatives: Match the Class to the Patient
Bulk-forming (ispaghula/psyllium, methylcellulose): first-line for chronic constipation; must be taken with adequate fluid and avoided in suspected obstruction or faecal impaction.
Osmotic (macrogol/polyethylene glycol, lactulose): draw water into the lumen; macrogol is first-line for chronic constipation and faecal loading, while lactulose is also used in hepatic encephalopathy to trap ammonium. Onset is 1-3 days.
Stimulant (senna, bisacodyl): increase peristalsis; reserve for short-term or opioid-induced constipation; overuse causes cramping and, historically, concern for cathartic colon.
Stool softeners (docusate): weak evidence; not recommended as sole therapy.
Antidiarrheals and Oral Rehydration
Loperamide , a peripheral opioid-receptor agonist, slows gut motility for symptomatic relief of acute non-bloody diarrhea. It must be avoided in bloody diarrhea, high fever or suspected invasive bacterial colitis (including C. difficile) , where delaying clearance of pathogens can precipitate toxic megacolon . The true mainstay of diarrhea management is fluid replacement: oral rehydration solution (ORS) exploits glucose-driven sodium co-transport in the small intestine - glucose absorption carries sodium and water with it, which is why ORS contains both glucose and electrolytes in defined proportions.
Inflammatory Bowel Disease and Gallstones
5-Aminosalicylates (5-ASAs) such as mesalazine are first-line for inducing and maintaining remission in mild-to-moderate ulcerative colitis, acting topically on the colonic mucosa; sulphasalazine's sulphapyridine moiety drives many of its side effects. For steroid-dependent or refractory disease, thiopurines (azathioprine, mercaptopurine) are used - check thiopurine methyltransferase (TPMT) status first because low TPMT activity causes severe myelosuppression , and monitor full blood counts regularly. Allopurinol dangerously raises thiopurine levels. Ursodeoxycholic acid is a hydrophilic bile acid that dissolves small cholesterol gallstones in patients unfit for surgery and slows disease progression in primary biliary cholangitis.
Dyspepsia Triage and NSAID Ulcer Prophylaxis
Community pharmacists are expected to distinguish simple dyspepsia from cases needing referral. Alarm features that mandate medical review include unintended weight loss, progressive dysphagia, persistent vomiting, gastrointestinal bleeding or iron-deficiency anemia, an abdominal mass, and new-onset symptoms in older patients. Without alarm features, short courses of antacids, an H2 blocker or a PPI trial are reasonable, with H. pylori test-and-treat considered for persistent symptoms. Patients who must continue NSAIDs and carry ulcer risk factors (age over 65, previous ulcer or bleed, concurrent corticosteroids, aspirin or anticoagulants) should receive gastroprotection with a PPI ; misoprostol , a prostaglandin E1 analogue, is the alternative but is limited by diarrhea and cramping and is absolutely contraindicated in pregnancy because of its uterotonic effect. Choosing the antiemetic by cause follows the same logic: 5-HT3 antagonists for chemotherapy and postoperative nausea, dopamine antagonists for drug-induced and gastroenteritic nausea, and antimuscarinics or sedating antihistamines such as cyclizine for motion sickness and vestibular causes.